Overall survival: Median length of · women with advanced ovarian cancer after PDS
Large‐volume residual disease (LVRD) > 1 cm probably leads to higher overall survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).
1 finding from 1 review
Progression‐free survival · women with advanced ovarian cancer after PDS
Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).
1 finding from 1 review
Overall survival: Median length of · women with advanced EOC after PDS
Large‐volume residual disease (LVRD) > 1 cm probably leads to higher overall survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (moderate certainty).
1 finding from 1 review
Progression‐free survival · women with advanced EOC after PDS
Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (moderate certainty).
1 finding from 1 review
Overall survival: Median length of · women with advanced EOC after primary IDS
It is very uncertain whether small‐volume residual disease (SVRD) (< 1 cm) changes overall survival: Median length of compared with NMRD (very low certainty).
1 finding from 1 review
Progression‐free survival · women with advanced EOC after primary IDS
1 finding from 1 review
Overall survival: Median length of · women with advanced EOC after primary IDS
It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes overall survival: Median length of compared with no macroscopic residual disease (NMRD) (very low certainty).
1 finding from 1 review
Chronic pelvic pain at 12 months Â
1 finding from 1 review
Dysmenorrhoea at 12 months Â
1 finding from 1 review
Improvement of the most troublesome symptom at 12 months Â
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life at 12 months Â
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction at 12 monthsÂ
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events Â
1 finding from 1 review
Â
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall pain at 12 months Â
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who were medication‐free (not using drops) at 12 months · people with open‐angle glaucoma
It is very uncertain whether phaco‐AIT changes proportion of participants who were medication‐free (not using… compared with phaco‐Trab (very low certainty).
1 finding from 1 review
Mean change in IOP measured in mmHg 12 months postintervention · people with open‐angle glaucoma
1 finding from 1 review
Mean change in number of IOP‐lowering drops from baseline · people with open‐angle glaucoma
1 finding from 1 review
Rate of visual field progression · people with open‐angle glaucoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean change in health‐related quality of life · people with open‐angle glaucoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found